Quest Diagnostics Inc (NYSE: DGX) has reported E.P.S. of $2.05 for its second fiscal quarter (ending June 30) versus $2.08 for the same period a year ago — a decline of -1%. This performance was $-0.28 short of the consensus estimate of $2.33. For the latest four quarters through June 30, E.P.S. were $7.50 compared to $6.97 a year ago — an increase of 8%.
Recent Price Action
Quest Diagnostics Inc (NYSE: DGX) stock closed at $140.96 on 7/23/24 after a decline of -4.3%. Moreover, trading volume in this decline was exceptionally high at 213% of normal. The stock has declined -2.5% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
DGX is expected to continue to be an important Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Quest Diagnostics has a current Value Trend Rating of C (Neutral). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Quest Diagnostics has a neutral Appreciation Score of 52 and a neutral Power Rating of 46, triggering the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment